Troriluzole

Chemical compound
Troriluzole
Clinical data
Other namesTrigriluzole, BHV-4157, FC-4157
Routes of
administration		By mouth
Identifiers
  • 2-amino-N-[2-[methyl-[2-oxo-2-[[6-(trifluoromethoxy)-1,3-benzothiazol-2-yl]amino]ethyl]amino]-2-oxoethyl]acetamide
CAS Number
  • 1926203-09-9
PubChem CID
  • 121488186
DrugBank
  • DB15079
ChemSpider
  • 58828005
UNII
  • S7H48S6K7H
KEGG
  • D11414
ChEMBL
  • ChEMBL4297586
Chemical and physical data
FormulaC15H16F3N5O4S
Molar mass419.38 g·mol−1
3D model (JSmol)
  • Interactive image
  • CN(CC(=O)NC1=NC2=C(S1)C=C(C=C2)OC(F)(F)F)C(=O)CNC(=O)CN
InChI
  • InChI=1S/C15H16F3N5O4S/c1-23(13(26)6-20-11(24)5-19)7-12(25)22-14-21-9-3-2-8(4-10(9)28-14)27-15(16,17)18/h2-4H,5-7,19H2,1H3,(H,20,24)(H,21,22,25)
  • Key:YBZSGIWIPOUSHY-UHFFFAOYSA-N

Troriluzole (trigriluzole) is an experimental medication that has been investigated as a potential treatment for spinocerebellar ataxia type 3 (SCA3),[1][2][3][4] obsessive-compulsive disorder,[3][4] and glioblastoma.[5] It is a prodrug formulation of the medication riluzole.[3][5]

Pharmacology

Pharmacokinetics

While riluzole is typically taken twice-daily and on an empty stomach, troriluzole may offer a potential once-daily dosing with or without food along with greater bioavailability.[3][5]

References

  1. ^ Meglio, Marco (25 June 2023). "Biohaven Submits New Drug Application for Troriluzole as Spinocerebellar Ataxia Type 3 Therapy". NeurologyLive. Retrieved 17 February 2024.
  2. ^ Waldron, James (27 July 2023). "Further blow for Biohaven as FDA refuses to consider failed rare disease drug for approval". Fierce Biotech. Retrieved 17 February 2024.
  3. ^ a b c d Grassi G, Cecchelli C, Vignozzi L, Pacini S (2020). "Investigational and Experimental Drugs to Treat Obsessive-Compulsive Disorder". Journal of Experimental Pharmacology. 12: 695–706. doi:10.2147/JEP.S255375. PMC 7801912. PMID 33447096.
  4. ^ a b van Roessel PJ, Grassi G, Aboujaoude EN, Menchón JM, Van Ameringen M, Rodríguez CI (January 2023). "Treatment-resistant OCD: Pharmacotherapies in adults". Comprehensive Psychiatry. 120: 152352. doi:10.1016/j.comppsych.2022.152352. hdl:2445/192315. PMID 36368186.
  5. ^ a b c Silk AW, Saraiya B, Groisberg R, Chan N, Spencer K, Girda E, Shih W, Palmeri M, Saunders T, Berman RM, Coric V, Chen S, Zloza A, Vieth J, Mehnert JM, Malhotra J (July 2022). "A phase Ib dose-escalation study of troriluzole (BHV-4157), an oral glutamatergic signaling modulator, in combination with nivolumab in patients with advanced solid tumors". European Journal of Medical Research. 27 (1): 107. doi:10.1186/s40001-022-00732-w. PMC 9250196. PMID 35780243.